LOGO

  • 1. °æÇÇ¿ë BCG ¹é½ÅÀÇ ¿¹¹æÈ¿°ú´Â °ËÁõµÇ¾î ÀÖ³ª¿ä?

    °æÇÇ¿ë BCG ¹é½ÅÀº BCG ¹é½Å Á¢Á¾ÀÇ ±¹¼Ò ÀÌ»ó¹ÝÀÀÀ» °æ°¨½Ã۰í
    Á¢Á¾ ÈÄ Åõº£¸£Ä𸰠¹ÝÀÀ(°áÇÙ±Õ¿¡ ´ëÇÑ ¹ÝÀÀ)ÀÇ ¾ç¼ºÀüȯÀ²ÀÌ Çdz»Á¢Á¾°ú µ¿µîÇÏ´Ù´Â
    µÎ °¡Áö ¿ì¼ö¼ºÀÌ È®ÀÎµÇ¾î °³¹ßµÈ ¹é½ÅÀÌ¿¡¿ä1.

    ÀÚ¼¼È÷º¸±â

    °æÇÇ¿ë BCG ¹é½ÅÀ» °³¹ßÇÑ ÀϺ»Àº 1967³âºÎÅÍ Çdz»Á¢Á¾¿¡¼­ °æÇÇÁ¢Á¾À¸·Î Àü¸é ÀüȯÇß°í2,
    Çѱ¹Àº 1993³â ½Ä¾àó¿¡¼­ ¹é½ÅÀÇ À¯È¿¼ºÀ» ÀÎÁ¤¹Þ¾Æ Á¤½ÄÇã°¡¸¦ ¹Þ¾Ò¾î¿ä3.
    °Ô´Ù°¡ ÇöÀç±îÁö ±¹³»¿¡ ¾à 700¸¸ ¸í ºÐ ÀÌ»óÀÌ °ø±Þ4µÇ¾î Á¢Á¾µÉ ¸¸Å­, dzºÎÇÑ ÀÓ»ó°æÇèÀ» º¸À¯Çϰí ÀÖ´ä´Ï´Ù.

    ÀÌ·¯ÇÑ °æÇÇ¿ë BCG ¹é½ÅÀÇ À¯È¿¼ºÀº ±¹³»¡¤¿Ü ¿©·¯ ÀÓ»óÀ» ÅëÇØ È®ÀεǾî ÀÖ±¸¿ä5-12.
    °æÇÇ¿ë BCG ¹é½ÅÀ¸·Î 100% Á¢Á¾Çϰí ÀÖ´Â ÀϺ»°ú,
    °æÇÇ¿ë BCG ¹é½Å Á¢Á¾·üÀÌ Àý¹Ý ÀÌ»óÀ» ³Ñ´Â Çѱ¹¿¡¼­
    ¼Ò¾Æ °áÇÙȯÀÚ¼ö(0¼¼~14¼¼)°¡ ¸Å³â ²ÙÁØÈ÷ °¨¼ÒµÇ°í ÀÖ´Â Åë°è13.14´Â,
    °æÇÇ¿ë BCG ¹é½ÅÀÇ ¿¹¹æÈ¿°ú¸¦ º¸¿©ÁÖ´Â ´ÜÀûÀÎ ¿¹Áö¿ä.

    [ÀϺ»¿¡¼­ 1967³â °æÇÇ¿ë BCG ¹é½Å µµÀÔÈÄ ½ÇÁ¦ ½Å°áÇ٠ȯÀÚ °¨¼ÒÀ²13]

    • - ÀϺ»Àº 1967³â Çdz»¿ë BCG ¹é½Å¿¡¼­ °æÇÇ¿ë BCG ¹é½ÅÀ¸·Î 100% ÀüȯµÊ2.
    • - 1967³â °æÇÇ¿ë BCG ¹é½Å µµÀÔ ÀÌÈÄ, ÀϺ»ÀÇ ¼Ò¾Æ°áÇÙȯÀÚ¼ö´Â ±Þ°ÝÇÏ°Ô °¨¼ÒÇÏ¿´À½13.

    [ Çѱ¹ÀÇ 0-14¼¼ ¼Ò¾Æ ½Å°áÇ٠ȯÀÚ¼ö ]14

    • - Çѱ¹¿¡¼­ Çdz»¿ë BCG ¹é½ÅÀº 1954³â NIP¿¡ óÀ½ µµÀÔ15µÇ¾ú°í,°æÇÇ¿ë BCG ¹é½ÅÀº 1994³â ¹ß¸ÅµÇ¾úÀ½

    ½ÇÁ¦·Î 2006³â °æÇÇÁ¢Á¾(Tokyo 172±ÕÁÖ), Çdz»Á¢Á¾(Tokyo 172±ÕÁÖ, Danish 1331±ÕÁÖ)¿¡ µû¸¥
    °¢°¢ÀÇ ¸é¿ª¹ÝÀÀÀ» ºñ±³¡¤Æò°¡ÇÑ ¹Ì±¹ °¨¿°º´ÇÐȸÀÇ ³í¹®¿¡ µû¸£¸é,
    °æÇÇÁ¢Á¾ÀÌ °°Àº Tokyo 172±ÕÁÖ¸¦ »ç¿ëÇÑ Çdz»Á¢Á¾À̳ª
    Danish ±ÕÁÖ¸¦ »ç¿ëÇÑ Çdz»Á¢Á¾¿¡ ºñÇØ
    Ȱ¹ßÇÑ ¸é¿ª¹ÝÀÀÀ» À¯µµÇÑ´Ù°í ¹ßÇ¥µÇ¾ú¾î¿ä5.

    ±× ¹Û¿¡ ±¹³»¿Ü¿¡¼­ Á¶»çµÈ ¸¹Àº ¿¬±¸¸¦ ÅëÇØ¼­µµ ¾ÈÀü¼º°ú À¯È¿¼ºÀÌ È®ÀÎµÈ ¹é½ÅÀ̶ø´Ï´Ù5-12.

    • Ref 1.
    • Ref 2.
    • Ref 3. °æÇÇ¿ë BCG ǰ¸ñ Çã°¡Áõ.
    • Ref 4. Çѱ¹¹é½Å BCG Vaccine Sales Data, 2015³â 12¿ù ±âÁØ.
    • Ref 5. Davids V, Hanekom W. A, Mansoor N, et al. The Effect of Bacille Calmette-Gue¢¥rin Vaccine Strain and Route of Administration on Induced Immune Responses in Vaccinated Infants. The journal of infactious Diseases 2006 : 193:531-536.
    • Ref 6. Hawkridge A, et al. Efficacy of percutaneous versus intradermal BCG in the prvention of tuberculosis in South African infants ranomised trial. BMJ(British Medical Journal) 2008;337:a2052.
    • Ref 7. ±è¿ì¼º, ±èâÈÖ ¿Ü 2ÀÎ. BCG Á¢Á¾¹æ¹ý¿¡ µû¸¥ °áÇÙ ¹ÝÀÀ°Ë»ç ¾çÀü·üÀÇ ºñ±³. ¼Ò¾Æ°ú Á¦ 40±Ç Á¦ 4È£ 1997.
    • Ref 8. ±è¿ÏÁÖ, À̼±È£ ¿Ü 3ÀÎ. °³¿ø°¡ÀÇ ½Å»ý¾Æ BCG Á¢Á¾ ÈÄ Åõº£¸£Ä𸰠¹ÝÀÀ Æò°¡. ¼Ò¾Æ°¨¿° Á¦ 9±Ç Á¦2È£ 2002.
    • Ref 9. ³ëÇý¿Á, ÀÌ¿ì±æ. °Ç°­ÇÑ ¿µ¾Æ¿¡¼­ °æÇÇ´ÙÀÚ¹ý BCG Á¢Á¾ÈÄ 2TU Åõº£¸£Ä𸰠°Ë»çÀÇ ¹ÝÀÀ¼º. ¼Ò¾Æ°¨¿° Á¦6±Ç Á¦1È£ 1999.
    • Ref 10. ±èº¸¼±, Ȳ¹ÎÈ£, ±èâÈÖ ¿Ü2ÀÎ. °æÇÇ¿ë BCG ¹é½ÅÀÇ PPD 1T U, 2T U ¹× 5T U °áÇÙ ÇǺιÝÀÀ °Ë»ç¿¡ ´ëÇÑ ¿µÇâ. ¼Ò¾Æ°¨¿° Á¦8±Ç Á¦2È£ 2001.
    • Ref 11. ÀÌÁø¼ö, ¼Õ¿µ¸ð. °æÇÇ¿ë °ÇÁ¶ B.C.G. ¹é½Å(Tokyo 172ÁÖ) Á¢Á¾ ÈÄ ±¹¼Ò ¹ÝÀÀ°ú Åõº£¸£Ä𸰠¾çÀüÀ²¿¡ °üÇÑ ¿¬±¸. ¼Ò¾Æ°¨¿° Á¦7±Ç Á¦2È£ 2000.
    • Ref 12. ¿À¸íÈ£, ±è±âÇõ, ½ÉÀç°Ç. ½Å»ý¾Æ¿¡¼­ °æÇÇ¿ë BCG Á¢Á¾ÈÄ ÇǺΠº¯È­¿Í °áÇÙ ¹ÝÀÀ ¾ç¼º·ü ¹× ÇÕº´Áõ¿¡ ´ëÇÑ °íÂû. ¼Ò¾Æ°ú Á¦40±Ç Á¦8È£ 1997.
    • Ref 13. JATA(ÀϺ»±¹¸³°áÇÙ¿¹¹æÇùȸ). ½Åµî·Ï ¼Ò¾Æ°áÇÙȯÀÚ¼ö ¹× ƯÁ¤Æó¿Ü°áÇÙ. °áÇÙÀÇ Åë°è 2016.
    • Ref 14. º¸°Çº¹ÁöºÎ. Åë°è¿¬º¸(1994~2000). Åë°èû °áÇÙ ½Å°í ½ÅȯÀÚ ÇöȲ(2001~2015).
    • Ref 15. ÀÌÁ¾±¸, ÃÖ¿ø¼®. ¿ì¸®³ª¶óÀÇ ¹é½Å Á¤Ã¥. °¨¿°°ú È­Çпä¹ý Á¦ 40±Ç Á¦ 1È£, 2008.
  • 2. °æÇÇ¿ë BCG¹é½Åµµ Çdz» BCG ó·³ ÀÏÁ¤·®ÀÇ ±ÕÁÖ¸¦ ÁÖÀÔÇÏ´Â ¹æ½ÄÀΰ¡¿ä?

    °æÇǹýÀº Çdz»¹ý°ú´Â ÀüÇô ´Ù¸¥ ÀÛ¿ë ±âÀüÀ» Áö´Ñ Á¢Á¾ ¹æ¹ýÀ̶ø´Ï´Ù.
    Á¢Á¾ ½Ã ÇÇÇÏÁ¢Á¾À¸·ÎÀÇ À§ÇèÀ» ÁÙÀ̰í,
    º¸´Ù ¾ÈÀüÇÏ°í Æí¸®ÇÑ Á¢Á¾À» À§ÇØ ÀϺ»¿¡¼­ °³¹ßµÈ Á¢Á¾ ¹æ½ÄÀä1

    ÀÚ¼¼È÷º¸±â

    °æÇǹýÀ̶õ, ÇǺο¡ 9°³ÀÇ ¹Ì¼¼ÇÑ °üħÀ¸·Î »óó¸¦ ³½ ÈÄ,
    ¾à¾×ÀÌ »óó »çÀÌ·Î ÀÚ¿¬½º·´°Ô ½º¸çµé°Ô ÇÏ´Â Á¢Á¾¹ýÀ¸·Î,
    ÇǺÎÇ¥¸éÀÇ °¢ÁúÃþ¿¡¼­ ÁøÇÇÃþ¿¡ À̸£±â±îÁö ÆÛÁ®ÀÖ´Â ÁöÁú, ¸ð³¶, ÇÇÁö¼±, ¶¡»ù µî¿¡ ÀÇÇØ
    ¾à¾×ÀÌ ºü¸£°Ô Èí¼öµÈ ÈÄ, Ç÷¾×ÀÇ È帧À» ÅëÇØ Àü½Å¿¡ ¿î¹ÝµÇ°Ô²û ÇÏ´Â Á¢Á¾ ¹æ½ÄÀ» ¸»ÇÑ´ä´Ï´Ù2.

    µû¶ó¼­, °æÇÇ¿ë BCG ¹é½ÅÀº ÇǺΠÀüü¸¦ ÅëÇØ ¾à¾×ÀÌ ºü¸£°Ô Èí¼öµÉ ¼ö ÀÖµµ·Ï
    ±Õ·®°ú ´ÜÀ§°¡ ÀüÇô ´Ù¸£°Ô ¼³Á¤(ml´ç ÀϺ» Çdz»¿ë BCG ¹é½Å ³óµµÀÇ ¾à 100¹è ÀÌ»ó)µÇ¾î ÀÖ¾î¿ä.3

    ÀÌ·¸µí Ư¼öÇÏ°Ô °í¾ÈµÈ ¾à¾×°ú °üħÀ» »ç¿ëÇØ Á¢Á¾ÇÒ °æ¿ì,
    Çdz»ÁÖ»ç·Î Á¢Á¾ÇßÀ»¶§¿Í µ¿ÀÏÇÑ Åõº£¸£Ä𸰹ÝÀÀ(°áÇÙ±Õ¿¡ ´ëÇÑ ¹ÝÀÀ) ¾çÀüÀ²À»
    ¾òÀ» ¼ö ÀÖ´Ù´Â »ç½ÇÀÌ ÀÓ»ó½ÃÇèÀ» ÅëÇØ Áõ¸íµÇ¾ú°í3,
    ±¹³»¿ÜÀÇ ¸¹Àº ¿¬±¸¸¦ ÅëÇØ ¹é½ÅÀÇ À¯È¿¼º°ú ¾ÈÀü¼º ¶ÇÇÑ È®ÀεǾî ÀÖ´ä´Ï´Ù4-11.

    • Ref 1.
    • Ref 2.À̹ÎÈ­¡¤±¸¿µ¼ø, ½Å¾àÁ¦ÇÐ Á¦ 3ÆÇ p466, 2004.
    • Ref 3.
    • Ref 4.Davids V, Hanekom W. A, Mansoor N, et al. The Effect of Bacille Calmette-Gue¢¥rin Vaccine Strain and Route of Administration on Induced Immune Responses in Vaccinated Infants. The journal of infactious Diseases 2006 : 193:531-536.
    • Ref 5.Hawkridge A, et al. Efficacy of percutaneous versus intradermal BCG in the prvention of tuberculosis in South African infants ranomised trial. BMJ(British Medical Journal) 2008;337:a2052.
    • Ref 6.±è¿ì¼º, ±èâÈÖ ¿Ü 2ÀÎ. BCG Á¢Á¾¹æ¹ý¿¡ µû¸¥ °áÇÙ ¹ÝÀÀ°Ë»ç ¾çÀü·üÀÇ ºñ±³. ¼Ò¾Æ°ú Á¦ 40±Ç Á¦ 4È£ 1997.
    • Ref 7.±è¿ÏÁÖ, À̼±È£ ¿Ü 3ÀÎ. °³¿ø°¡ÀÇ ½Å»ý¾Æ BCG Á¢Á¾ ÈÄ Åõº£¸£Ä𸰠¹ÝÀÀ Æò°¡. ¼Ò¾Æ°¨¿° Á¦ 9±Ç Á¦2È£ 2002.
    • Ref 8.³ëÇý¿Á, ÀÌ¿ì±æ. °Ç°­ÇÑ ¿µ¾Æ¿¡¼­ °æÇÇ´ÙÀÚ¹ý BCG Á¢Á¾ÈÄ 2TU Åõº£¸£Ä𸰠°Ë»çÀÇ ¹ÝÀÀ¼º. ¼Ò¾Æ°¨¿° Á¦6±Ç Á¦1È£ 1999.
    • Ref 9.±èº¸¼±, Ȳ¹ÎÈ£, ±èâÈÖ ¿Ü2ÀÎ. °æÇÇ¿ë BCG ¹é½ÅÀÇ PPD 1T U, 2T U ¹× 5T U °áÇÙ ÇǺιÝÀÀ °Ë»ç¿¡ ´ëÇÑ ¿µÇâ. ¼Ò¾Æ°¨¿° Á¦8±Ç Á¦2È£ 2001.
    • Ref 10.ÀÌÁø¼ö, ¼Õ¿µ¸ð. °æÇÇ¿ë °ÇÁ¶ B.C.G. ¹é½Å(Tokyo 172ÁÖ) Á¢Á¾ ÈÄ ±¹¼Ò ¹ÝÀÀ°ú Åõº£¸£Ä𸰠¾çÀüÀ²¿¡ °üÇÑ ¿¬±¸. ¼Ò¾Æ°¨¿° Á¦7±Ç Á¦2È£ 2000.
    • Ref 11.¿À¸íÈ£, ±è±âÇõ, ½ÉÀç°Ç. ½Å»ý¾Æ¿¡¼­ °æÇÇ¿ë BCG Á¢Á¾ÈÄ ÇǺΠº¯È­¿Í °áÇÙ ¹ÝÀÀ ¾ç¼º·ü ¹× ÇÕº´Áõ¿¡ ´ëÇÑ °íÂû. ¼Ò¾Æ°ú Á¦40±Ç Á¦8È£ 1997.
  • 3. °æÇÇ¿ë BCG ¹é½Å Á¢Á¾Àº ±â¼úÀûÀ¸·Î ¾î·Á¿î°¡¿ä?

    °æÇÇÁ¢Á¾Àº ±â¼úÀûÀ¸·Î º¹ÀâÇϰí Á¢Á¾ÀÚ¿¡ µû¶ó °³ÀÎÂ÷°¡ Å©´Ù°í °£È¤ ¾ð±ÞµÇÁö¸¸,
    ÀÌ´Â À߸ø ¾Ë·ÁÁø ³»¿ëÀÌ¿¡¿ä.

    ÀÚ¼¼È÷º¸±â

    [°æÇÇ¿ë BCG Á¢Á¾¹æ¹ý]

    °æÇÇ¿ë BCG ¹é½ÅÀÇ Á¦Á¶±¹ÀÎ ÀϺ»Àº ÇöÀç±îÁö 50³â°£ 100% °æÇÇ¿ë BCG ¹é½ÅÀ» Á¢Á¾Çϰí Àִµ¥¿ä,
    Á¢Á¾ ±¹¼Ò¹ÝÀÀÀÇ °æ°¨°ú Åõº£¸£Ä𸰠¹ÝÀÀ(°áÇÙ±Õ¿¡ ´ëÇÑ ¹ÝÀÀ)ÀÇ ¾ç¼ºÀüȯÀ²ÀÌ
    Çdz»Á¢Á¾°ú µ¿µîÇÏ´Ù´Â Á¡ À̿ܿ¡µµ Á¢Á¾ ±â¼úÀÌ º¸´Ù ½±´Ù´Â Á¡ ¿ª½Ã °æÇǹýÀÇ ÀåÁ¡À¸·Î ²ÅÈ÷°í ÀÖ´ä´Ï´Ù1.

    °æÇǹýÀº Á¦´ë·Î Á¢Á¾ °­½ÀÀ» ¹Þ°Ô µÇ¸é, ¾î·Á¿î ±â¼ú ¾øÀ̵µ ¿Ã¹Ù¸¥ Á¢Á¾ÀÌ °¡´ÉÇØ¿ä1.

    • Ref 1.
  • 4. °æÇÇ¿ë BCG ¹é½ÅÀº ºÎÀÛ¿ë¿¡ ´ëÇÑ º¸»óÀ» ¹ÞÀ» ¼ö ÀÖ³ª¿ä?

    °æÇÇ¿ë BCG ¹é½ÅÀº ÇöÀç ±¹°¡Çʼö¿¹¹æÁ¢Á¾(NIP)¿¡ ÇØ´çµÇÁö ¾Ê±â ¶§¹®¿¡,
    ÀÌ»ó¹ÝÀÀÀÌ ¹ß»ýÇßÀ» °æ¿ì ¿¹¹æÁ¢Á¾ÇÇÇØ ±¹°¡º¸»ó ÀýÂ÷¸¦ ÅëÇØ º¸»ó¹ÞÀ» ¼ö ¾ø¾î¿ä.
    ÇÏÁö¸¸, ¼öÀÔ¿øÀÎ ÀúÈñ ¢ßÇѱ¹¹é½Å»ó»ç¿¡¼­´Â ÀÚ»ç ±âÁØ¿¡ ÀǰÅÇÏ¿©
    ÀÌ»ó¹ÝÀÀ °ü·Ã ÀÚü Áö¿øÀ» Á¦Ç° Ãâ½Ã ÀÌ·¡ Áö¼ÓÀûÀ¸·Î ½Ç½ÃÇØ¿À°í ÀÖ¾ú´ä´Ï´Ù.

    ÀÚ¼¼È÷º¸±â

    2017³â 1¿ùºÎÅÍ ¾à»ç¹ý Á¦ 86Á¶¿¡ µû¶ó ½ÄǰÀǾàǰ¾ÈÀüó »êÇÏ Çѱ¹ÀǾàǰ¾ÈÀü°ü¸®¿øÀÇ
    ÀǾàǰ ºÎÀÛ¿ë ÇÇÇØ ±¸Á¦Á¦µµ¸¦ ÅëÇØ, '2014³â 12¿ù 19ÀÏ ÀÌÈÄ ¹ß»ýÇÑ' °æÇÇ¿ë BCG ¹é½Å °ü·Ã ÀÌ»ó¹ÝÀÀ °ÇµéÀÇ ÇÇÇØº¸»óÀ»
    ±¹°¡¿¡ ½ÅûÇÒ ¼ö ÀÖ´Ù´Â ±â»çµµ ¾ó¸¶ Àü¿¡ º¸µµµÇ¾úÁö¿ä.
    (±â»ç ¿ø¹® : http://www.newspim.com/news/view/20160906000104)

    Áï, 2017³â 1¿ùºÎÅÍ Á¢Á¾ÀÏ ±âÁØÀ¸·Î 2³â Àü¿¡ Á¢Á¾ÇÏ¿© ºÎÀÛ¿ëÀÌ »ý±ä °æ¿ì,
    ÀǾàǰ ºÎÀÛ¿ë ÇÇÇØ ±¸Á¦Á¦µµ¸¦ ÅëÇØ¼­ º¸»ó ¹ÞÀ» ¼ö ÀÖ¾î¿ä.

    (»ç¸Á, Àå¾Ö°¡ ¹ß»ýÇÏ¿´°Å³ª Áúº´ÀÌ ¹ß»ýÇÏ¿© ÀÔ¿øÄ¡·á¸¦ ¹ÞÀ¸½Å ºÐµé Áß ±¹¹Î°Ç°­º¸Çè¹ý ¶Ç´Â
    ÀÇ·á±Þ¿©¹ý¿¡ µû¶ó º»Àκδã±Ý 30¸¸¿ø ÀÌ»óÀÏ °æ¿ì Àû¿ëµÊ.
    ´Ü, º´¿øÄ¡·á ¾øÀÌ È£ÀüµÇ¾ú°Å³ª Åë¿øÄ¡·á¸¸À¸·Î È£ÀüµÈ °æ¿ì Á¦¿ÜµÊ.)
    ±×·¯³ª ÀǾàǰ ºÎÀÛ¿ë ÇÇÇØ ±¸Á¦Á¦µµ º¸»óÀýÂ÷ Á¶°Ç¿¡ ºÎÇÕ µÇÁö ¾Ê´Â °æ¿ì, ÀÚ»ç ±âÁØ¿¡ µû¶ó Áö¿øÀÌ °¡´ÉÇϱ⵵ ÇØ¿ä.

    ÀÚ»ç Áö¿ø ±âÁØÀº ¾Æ·¡¿Í °°´ä´Ï´Ù.

    Áö¿ø¹üÀ§ ¿¹¹æÁ¢Á¾ÇÇÇØ±¹°¡º¸»óÀýÂ÷°¡ º¸ÀåÇÏ´Â °Í°ú µ¿ÀϹüÀ§ ¹×
    Àڻ簡 µ¿ÀÇÇÏ´Â ºÎ´ëºñ¿ë
    Áö¿øÈ½¼ö Ä¡·á°¡ ¿Ï·áµÇ´Â ½ÃÁ¡±îÁö Ƚ¼ö¿¡ »ó°ü¾øÀÌ Áö¿ø
    Áö¿ø½Åû ±âÁØ ±Ý¾× ±¹¹Î°Ç°­º¸Çè¹ý ¶Ç´Â ÀÇ·á±Þ¿©¹ý¿¡ Áø·á½ÇºñÁö¿ø
    (´Ü, ºñ±Þ¿©´Â ÀÚ»ç¿Í ÇùÀÇ ÈÄ Áö¿ø°¡´É)
    Áö±Þ±âÀÏ Á¢¼ö ÈÄ ÃÖ´ëÇÑ ½Å¼ÓÈ÷ ½ÉÀÇ, ÇÊ¿ä ¼­·ù ¼ö·É ÈÄ ¿µ¾÷ÀÏ 5ÀÏ À̳» Áö±Þ
    Çʿ伭·ù Áø´Ü¼­(¼Ò°ß¼­), ÀÔ¿ø ¹× ¼ö¼ú½Ã(ÀÔ·Åð¿øÈ®Àμ­), Áø·áºñ¿µ¼öÁõ,
    Áֹεî·Ïµîº»(°¡Á·°ü°èÁõ¸í¼­), ÅëÀå»çº», °³ÀÎÁ¤º¸µ¿ÀǼ­

    ÀÌ»ó¹ÝÀÀ¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ »ó´ãÀ» ¿øÇϽô ºÐÀº
    ¢ß Çѱ¹¹é½Å(Tel :02-443-1961)·Î ¿¬¶ôÁֽøé Ä£ÀýÇÏ°Ô ¾È³»Çص帮µµ·Ï ÇϰڽÀ´Ï´Ù.

  • 5. °æÇÇ¿ë BCG ¹é½ÅÀ¸·Î Á¢Á¾Çϸé ÈäÅͰ¡ ¾È »ý±â³ª¿ä?

    ±×·¸Áö ¾Ê½À´Ï´Ù,
    BCG ¹é½ÅÀÇ Á¢Á¾ ÈäÅÍ(¹ÝÈç)´Â ¾ÆÀÌÀÇ »ì¼º µî ´Ù¾çÇÑ ¿äÀο¡ µû¶ó ³²À» °¡´É¼ºÀÌ ÀÖ°í
    ÈäÅÍ(¹ÝÈç)ÀÇ »óųª °³¼ö ¿ª½Ã Â÷À̰¡ ÀÖÀ» ¼ö ÀÖ¾î¿ä1-5.

    ÀÚ¼¼È÷º¸±â

    ½ÇÁ¦·Î °æÇÇ¿ë BCG ¹é½ÅÀº 9°³ÀÇ ¹Ì¼¼ÇÑ Ä§ÀÌ ÀÏÁ¤ °£°ÝÀ¸·Î ¹èÄ¡µÇ¾î,
    Á¢Á¾ ±¹¼Ò ºÎÀ§¿¡ °¡ÇØÁö´Â ÈûÀ» ºÐ»ê½Ãų ¼ö ÀÖµµ·Ï °í¾ÈµÇ¾ú´ä´Ï´Ù.

    Áï, ¾ÆÀÌ »ì¼º¿¡ µû¶ó Â÷ÀÌ´Â ÀÖ°ÚÁö¸¸ ±âº»ÀûÀ¸·Î ±¹¼Ò ¹ÝÀÀÀÌ Àûµµ·Ï ¼³°èµÈ °ÍÀ¸·Î6
    °æÇÇ¿ë BCG ¹é½ÅÀ» Á¢Á¾ÇÑ ÈÄ ¸î ³âÀÌ Áö³ª¸é ÈäÅÍ(¹ÝÈç)°¡ Èñ¹ÌÇÑ ÀÚ±¹À¸·Î ³²°Ô µË´Ï´Ù.

    • Ref 1.±èÁ¾Çö ¿Ü 6ÀÎ. The Number of Scars in Percutaneous Tokyo Strain BCG is not a Reliable Parameter
      to Appraise the BCG Immune Reactions. ¼Ò¾Æ°¨¿°º´ÇÐȸ ÃÊ·ÏÁý 2012³â.
    • Ref 2.ÀÌÁø¼ö, ¼Õ¿µ¸ð. °æÇÇ¿ë °ÇÁ¶B.C.G.¹é½Å (Tokyo 172ÁÖ) Á¢Á¾ ÈÄ ±¹¼Ò ¹ÝÀÀ°ú Åõº£¸£Ä𸰠¾çÀüÀ²¿¡ °üÇÑ ¿¬±¸. ¼Ò¾Æ°¨¿° Á¦7±Ç Á¦2È£ p201-210, 2000³â.
    • Ref 3.´ëÇѼҾưúÇÐȸ. BCG(Bacille Calmette-Guerin) ¹é½Å. ¿¹¹æÁ¢Á¾Áöħ¼­ Á¦8ÆÇ. p65, 2015³â.
    • Ref 4.Áúº´°ü¸®º»ºÎ. ¿¹¹æÁ¢Á¾ ´ë»ó °¨¿°º´ÀÇ ¿ªÇаú °ü¸®. ¿¹¹æÁ¢Á¾ ½Ç½Ã ±âÁØ ¹× ¹æ¹ý Á¦ 4ÆÇ ¼öÁ¤ÆÇ p75, 2013³â.
    • Ref 5.
    • Ref 6.
  • 6. BCG ¹é½Å Á¢Á¾ ÈÄ Á¢Á¾ÈçÀÌ º¸ÀÌÁö ¾ÊÀ¸¸é, ÀçÁ¢Á¾ÇØ¾ß Çϳª¿ä?

    Á¢Á¾ ÈÄ ¹ß»ýÇÏ´Â ÈäÅÍ(¹ÝÈç)´Â ¾ÆÀÌÀÇ »ì¼º µî¿¡ ¿µÇâÀ» ¹Þ´Â´ä´Ï´Ù.
    ±¹³»¡¤¿Ü¿¡ ¹ßÇ¥µÈ Àڷᳪ ³í¹®¿¡¼­µµ Á¢Á¾ ÈÄ ¹ß»ýÇÑ ÈäÅÍ(¹ÝÈç)ÀÇ °³¼ö´Â °³Àθ¶´Ù Â÷À̰¡ ÀÖ¾ú°í,
    ÈäÅÍ(¹ÝÈç)°¡ ³²Áö ¾Ê´Â °æ¿ìµµ ÀÖ¾ú¾î¿ä1-5.

    ÀÚ¼¼È÷º¸±â

    ÇÏÁö¸¸, ÈäÅÍ(¹ÝÈç)ÀÇ °³¼ö°¡ °áÇÙ¿¡ ´ëÇÑ ¸é¿ª·Â Çü¼ºÀ» ÆÇ´ÜÇÏ´Â ±âÁØÀÌ ¾Æ´Ï¶ó´Â »ç½ÇÀÌ ÀÌ¹Ì ¹ßÇ¥µÇ¾ú°í1-5,

    ±¹³» ¼Ò¾Æ°úÇÐȸÀÇ BCG Á¢Á¾Áöħ¿¡¼­µµ,
    ¡®Á¢Á¾·ÂÀÌ ÀÖ´Ù¸é, ÈäÅÍ(¹ÝÈç)°¡ ¾ø´Ù ÇØµµ ÀçÁ¢Á¾À» ±ÇÀåÇÏÁö´Â ¾Ê´Â´Ù¡¯ ¶ó°í ±âÀçµÇ¾î ÀÖ´ä´Ï´Ù3.

    • Ref 1.±èÁ¾Çö ¿Ü 6ÀÎ. The Number of Scars in Percutaneous Tokyo Strain BCG is not a eliable Parameter to Appraise the BCG Immune Reactions. ¼Ò¾Æ°¨¿°º´ÇÐȸ ÃÊ·ÏÁý 2012³â.
    • Ref 2.ÀÌÁø¼ö, ¼Õ¿µ¸ð. °æÇÇ¿ë °ÇÁ¶B.C.G.¹é½Å (Tokyo 172ÁÖ) Á¢Á¾ ÈÄ ±¹¼Ò ¹ÝÀÀ°ú Åõº£¸£Ä𸰠¾çÀüÀ²¿¡ °üÇÑ ¿¬±¸. ¼Ò¾Æ°¨¿° Á¦7±Ç Á¦2È£ p201-210, 2000³â.
    • Ref 3.´ëÇѼҾưúÇÐȸ. BCG(Bacille Calmette-Guerin) ¹é½Å. ¿¹¹æÁ¢Á¾Áöħ¼­ Á¦8ÆÇ. p65, 2015³â.
    • Ref 4.Áúº´°ü¸®º»ºÎ. ¿¹¹æÁ¢Á¾ ´ë»ó °¨¿°º´ÀÇ ¿ªÇаú °ü¸®. ¿¹¹æÁ¢Á¾ ½Ç½Ã ±âÁØ ¹× ¹æ¹ý Á¦ 4ÆÇ ¼öÁ¤ÆÇ p75, 2013³â.
    • Ref 5.
  • 7. WHO¿¡¼­´Â Çdz»¿ë BCG ¹é½ÅÀ» ±ÇÀåÇÑ´Ù´øµ¥ ÀÌÀ¯°¡ ÀÖ³ª¿ä?

    °ú°Å WHO´Â Çdz»¿ë BCG ¹é½ÅÀ» ±ÇÀåÇÑ´Ù(recommends)°í ÇßÀ¸³ª,
    2018³â 2¿ù ¹ßÇàµÈ WHOÀÇ Weekly epidemiological recordÀÇ
    BCG Vaccines WHO Position paper¸¦ ÅëÇØ ¡°±ÇÀåÇÑ´Ù(recommends)¡±´Â ¹®±¸°¡ »èÁ¦µÇ¾ú°í
    ´ÙõÀÚħÀ» ÀÌ¿ëÇÑ °æÇÇ Åõ¿©¹ý »ç¿ëÀÌ Çã¿ëµÈ Á¦Ç°ÀÌ Á¸ÀçÇÔÀ» È®ÀÎÇÒ ¼ö ÀÖ¾î¿ä
    ÀÌ¿ÍÇÔ²² WHO´Â ´Ù¾çÇÑ BCG ¹é½Å Á¦Ç°µéÀÇ »ç¿ë¿¡ ÀÖ¾î ¼±È£µÇ´Â Á¦Ç°Àº ¾øÀ¸¸ç
    À̴ ƯÁ¤ ¿¬·ÉÀ̳ª À§Çè±×·ì¿¡¼­µµ ¸¶Âù°¡ÁöÀÓÀ» Ç¥¸íÇßÁö¿ä1-2.

    Âü°í·Î ¼±Áø±¹¿¡¼­´Â Çdz»¿ë BCG ¹é½ÅÀÌ ¾Æ´Ñ °æÇÇ¿ë BCG ¹é½ÅÀ» °³¹ßÇß¾î¿ä.
    Áï ¹Ì±¹, ¿µ±¹, ÇÁ¶û½º, ÀϺ»¿¡¼­ °æÇÇ¿ë BCG ¹é½ÅÀ» °¢°¢ °³¹ßÇßÁö¸¸3-6
    ÇöÀç ¼±Áø±¹µé ´ëºÎºÐÀº »ó´ëÀûÀ¸·Î °áÇٹߺ´·üÀÌ ³·¾Æ¼­,
    BCG ¹é½Å Á¢Á¾À» ¿ì¸®³ª¶ó³ª ÀϺ»Ã³·³ ±¹°¡¿¹¹æÁ¢Á¾À¸·Î äÅÃÇϰí ÀÖÁö´Â ¾Ê´ä´Ï´Ù.

    ÀÚ¼¼È÷º¸±â

    °áÇÙÀº ÁÖ·Î °³¹ßµµ»ó±¹°¡¿¡¼­ ¹ß»ýÇØ¿ä.
    ´ëºÎºÐÀº ¾Æ½Ã¾Æ(55%)¿Í ¾ÆÇÁ¸®Ä«(30%)¿¡¼­ ¹ß»ýÇϰí ÀÖ°í,
    ±¹°¡º°·Î´Â Àεµ(200¸¸¸í), Áß±¹(130¸¸¸í), ³²¾ÆÇÁ¸®Ä«°øÈ­±¹(49¸¸¸í), ³ªÀÌÁö¸®¾Æ(46¸¸¸í),
    Àεµ³×½Ã¾Æ(43¸¸¸í) ¼øÀ¸·Î ¸¹´ä´Ï´Ù7.

    WHO(¼¼°èº¸°Ç±â±¸)´Â UNICEF(À¯´Ï¼¼ÇÁ : UN»êÇÏ ¾Æµ¿±¸È£±â°ü)¸¦ ÅëÇØ,
    Çdz»¿ë BCG ¹é½ÅÀ» °ø±ÞÇϰí Àִµ¥¿ä8.
    Çdz»¿ë BCG ¹é½ÅÀº ÇÑ ¹ÙÀ̾Ë(º´) ´ç ÃÖ´ë 20¸í±îÁö Á¢Á¾ÇÒ ¼ö ÀÖ´Â ´ÙÀÎ¿ë ¹é½ÅÀ¸·Î
    1ÀÎ 1ȸ¿ë ¹é½ÅÀÎ °æÇÇ¿ë BCG ¹é½Å°ú´Â Â÷À̰¡ ÀÖ¾î¿ä.

    ±× µ¿¾È WHO°¡ Çdz»¿ë BCG¸¦ ±ÇÀåÇß´ø °ÍÀº, WHO°¡ ¹ü±¹°¡ÀûÀÎ ´ë±Ô¸ð °¨¿° ¿¹¹æÀ̶ó´Â ¸ñÀû¿¡ µû¶ó,
    ¹é½ÅÀÇ À¯È¿¼º ¹× ¾ÈÀü¼º, ¹é½Å ±¸¸Åºñ¿ë, ±×¸®°í Á¢Á¾±¹°¡µéÀÇ »óȲ µî
    Á¾ÇÕÀûÀÎ ÆÇ´Ü¿¡ µû¸¥ °ÍÀ̶ó°í »ý°¢ÇÒ ¼ö ÀÖ¾î¿ä.

    Âü°í·Î Çdz»¿ë BCG ¹é½ÅÀº 1928³â¿¡ °³¹ßµÈ Á¢Á¾¹ýÀ̰í9,
    9°³ÀÇ °üħÀ» »ç¿ëÇÑ °æÇÇ¿ë BCG ¹é½ÅÀº 1964³â¿¡ ÀϺ»¿¡¼­ °í¾ÈµÇ¾ú´Âµ¥¿ä9.
    ÀϺ»ÀÇ °æ¿ì Çdz»¿ë BCG ¹é½Å ¿ª½Ã »ý»êÇϰí ÀÖÁö¸¸,
    ÀÚ±¹¹ÎÀº 100% °æÇÇ¿ë BCG ¹é½ÅÀ» Á¢Á¾Çϰí,
    »ý»êµÇ´Â Çdz»¿ë BCG ¹é½ÅÀº Àü·® ¼öÃâÇϰí ÀÖ¾î¿ä.

    Âü°í·Î °æÇÇ¿ë BCG ¹é½ÅÀÇ 'Tokyo 172±ÕÁÖ'´Â
    1965³â¿¡ WHO Reference Reagent(WHO ±¹Á¦Ç¥ÁØÇ°)·Î ¼±Á¤µÇ¾ú°í9
    ±¹Á¦ÀûÀÎ °øµ¿¿¬±¸¸¦ ÅëÇØ Æò°¡µÈµ¥´Ù,
    2009³â 10¿ù WHO ECBS(¼¼°èº¸°Ç±â±¸ »ý¹°ÀǾàǰ Ç¥ÁØÈ­ Àü¹®°¡À§¿øÈ¸)¿¡ ÀÇÇØ
    äÅÃµÈ ±ÕÁÖÀ̱⵵ ÇØ¿ä10.

    • Ref 1.World Health Organization, WEEKLY EPIDEMIOLOGICAL RECORD, NO. 4, 23 JANUARY 2004, 34p.
    • Ref 2 .World Health Organization, WEEKLY EPIDEMIOLOGICAL RECORD, NO 8, 23 FEBRUARY 2018, 84p, 96p.
    • Ref 3.Merck Homepage>Products>Vaccines&Prescribing Information, http://www.merck.com/product/
    • Ref 4.Percutaneous BCG Vaccine BP, The Open University,
      http://mcs.open.ac.uk/nlg/old_projects/pills/corpus/pil/data/Evans/Percutaneous_BDG_Vaccine_BP/Percutaneous_BDG_Vaccine_BP.html
    • Ref 5.FRENCH INSTITUTE FOR PUBLIC HEALTH SURVEILLANCE, Low BCG Vaccination coverage after the end of compulsory vaccination in Ile-de-France(France), a region of high tuberculosis incidence, Otc. 2009.
    • Ref 6.Japan BCG Laboratory Homepage>Our Products for Overseas Market, http://www.bcg.gr.jp/english/menu1.html
    • Ref 7.´ëÇѼҾưúÇÐȸ, ¿¹¹æÁ¢Á¾Áöħ¼­ Á¦ 8ÆÇ 54p, 2015.
    • Ref 8.UNICEF, UNICEF information to countries on constrained BCG vaccine market, Available at : http://www.unicef.org/supply/index_82351.html
    • Ref 9.
    • Ref 10.NIBSC(The National Institute for Biological Standards and Control), BCG Standardisation, 2014.
  • 8. °æÇÇ¿ë BCG ¹é½ÅÀº Á¢Á¾ ÈÄ ÀÌ»ó¹ÝÀÀÀÌ ¸¹ÀÌ ¹ß»ýÇϳª¿ä?

    ±×·¸Áö ¾Ê¾Æ¿ä.
    ÀϺ» Á¤ºÎ¿¡¼­´Â ±âÁ¸¿¡ »ç¿ëÇÏ´ø Çdz»¿ë BCG ¹é½ÅÀÇ ÀÌ»ó¹ÝÀÀ ¹®Á¦·Î
    1967³â °æÇÇ¿ë BCG ¹é½ÅÀ¸·Î ÀüȯÇÏ¿©
    ÇöÀç±îÁö °æÇÇ¿ë BCG ¹é½Å¸¸À» 100% »ç¿ëÇϰí ÀÖ¾î¿ä1.

    ÀÚ¼¼È÷º¸±â

    °æÇÇ¿ë BCG ¹é½ÅÀº ±¹¼Ò ¹ÝÀÀÀ» Æ÷ÇÔÇÑ ÀÌ»ó¹ÝÀÀ ¹ßÇöÀ²ÀÌ Çdz»¿ë BCG ¹é½Å¿¡ ºñÇØ
    »ó´ëÀûÀ¸·Î Àû´Ù°í ¾Ë·ÁÁ® ÀÖ¾î¿ä2.

    ±¹¡¤³»¿ÜÀÇ ¹®ÇåÀ» ÅëÇØ¼­µµ °æÇÇ¿ë BCG ¹é½ÅÀÌ Çdz»¿ë BCG ¹é½Åº¸´Ù ºÎÀÛ¿ëÀÌ Àû´Ù´Â Á¡ÀÌ º¸°íµÇ¾ú°í3.4
    ½ÇÁ¦·Î °æÇÇÁ¢Á¾À¸·Î Àϰý ÀüÈ¯ÇØ¼­ 50³â °¡±îÀÌ °æÇÇ¿ë BCG ¹é½Å¸¸ Á¢Á¾ ÁßÀÎ ÀϺ»¿¡¼­µµ
    ³ôÀº ¹æ¾îÈ¿°ú¿Í ³·Àº ÀÌ»ó¹ÝÀÀ ¹ßÇöÀ²À» º¸À̰í ÀÖÁö¿ä2.5.


    ÀÌ»ó¹ÝÀÀÀÌ »ó´ëÀûÀ¸·Î ³·Áö¸¸,
    ¢ßÇѱ¹¹é½Å¿¡¼­´Â °æÇÇ¿ë BCG ¹é½ÅÀÇ Ãâ½Ã ÀÌ·¡·Î ÀÌ»ó¹ÝÀÀ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú
    ÀÚ»ç ±ÔÁ¤¿¡ ÀǰÅÇÑ º¸»ó Á¤Ã¥ ¶ÇÇÑ ²ÙÁØÈ÷ ½Ç½ÃÇØ¿À°í ÀÖ´ä´Ï´Ù.
    (Çѱ¹¹é½Å º¸»ó Á¤Ã¥ : FAQ 4¹ø ÂüÁ¶)

    • Ref 1.
    • Ref 2.Plotkin SA, Orenstein WA, Offit PA. Vaccines. 6th ed. P789-811, Philadelphia, Elsevier Inc., 2013.
    • Ref 3.±èÁ¾Çö, °¡Å縯´ëÇб³ Àǰú´ëÇÐ, BCG ¹é½ÅÀÇ À¯¿ë¼º Æò°¡-BCG ¹é½Å ¸²ÇÁÀý¿° ¹ß»ý¾Æ¿¡ ´ëÇÑ ¸é¿ª»óÅ Á¶»ç, 10 Feb. 2010.
    • Ref 4.WHO(World Health Organization), Weekly Epidemiological Record, 382p, 9 Dec. 1988.
    • Ref 5.JATA(Japan Anti-tuberculosis Association) ½Åµî·Ï ¼Ò¾Æ°áÇÙȯÀÚ¼ö ¹× ƯÁ¤Æó¿Ü°áÇÙ, °áÇÙÀÇ Åë°è 2016.
  • 9. °æÇÇ¿ë BCG ¹é½ÅÀº ¹æ»ç´É °Ë»ç¸¦ ÁøÇàÇϳª¿ä?

    °æÇÇ¿ë BCG ¹é½Å¿¡´Â ¹æ»ç¼º ¹°ÁúÀÌ Æ÷ÇԵǾîÀÖÁö ¾Ê½À´Ï´Ù1

    ÀÚ¼¼È÷º¸±â

    ±×·³¿¡µµ ºÒ±¸Çϰí 2011³â ÀÌÈÄ ¼öÀÔ¿øÀÎ ÀúÈñ ¢ßÇѱ¹¹é½Å»ó»ç¿¡¼­´Â
    ÀϺ» Á¦Á¶¼Ò·ÎºÎÅÍ °æÇÇ¿ë BCG ¹é½Å¿¡ ´ëÇÑ ¹æ»ç¼±·® Á¶»ç µ¥ÀÌÅ͸¦
    üũÇÏ¿© ¹æ»ç¼±¿¡ ´ëÇÑ ¹®Á¦°¡ ¾øÀ½À» È®ÀÎÇϰí ÀÖ½À´Ï´Ù.
    µû¶ó¼­ ¾È½ÉÇÏ½Ã°í °æÇÇ¿ë BCG ¹é½ÅÀ» Á¢Á¾Çϼŵµ ±¦Âú½À´Ï´Ù.


    ¢ßÇѱ¹¹é½ÅÀº ¾ÕÀ¸·Îµµ öÀúÇÑ Ç°Áú°ü¸®¸¦ ÅëÇØ,
    ¼ÒÁßÇÑ ¿ì¸® ¾ÆÀ̵éÀÇ °Ç°­ ÁöÅ´À̷μ­ ÃÖ¼±À» ´ÙÇÒ °ÍÀ» ¾à¼Óµå¸³´Ï´Ù.

    • Ref 1.°æÇÇ¿ë°ÇÁ¶ºñ¾¾Áö¹é½Å(ÀϺ»±ÕÁÖ) ǰ¸ñ Çã°¡Áõ.